Berg, Boehringer Ingelheim partner on inflammatory disease research

By Jenni Spinner contact

- Last updated on GMT

(Image: Getty/peterschreiber.media)
(Image: Getty/peterschreiber.media)

Related tags: Inflammation, Clinical research, data analysis

The research collaboration will seek to identify candidate biomarkers for a group of inflammatory conditions, using AI and other advanced technology.

Berg—a clinical-stage company that incorporates artificial intelligence (AI) to research various diseases and develop novel treatments for those conditions—is joining forces with pharmaceutical firm Boehringer Ingelheim, using its Interrogative Biology platform. The two firms will work together on research projects centered on better understanding the spectrum of inflammatory diseases, and their associated biological drivers.

According to Berg, the pilot program working with Boehringer Ingelheim is geared toward revealing new insights into the complexities of various inflammatory diseases. The possible outcomes of the research partnership, the participants hope, will lead to an increased understanding of the etiology of potential candidate biomarkers.

Niven Narain (Berg cofounder, president and CEO) said the two companies hope to advance tests and treatments for people diagnosed with such inflammatory diseases.

“We’re excited to partner with Boehringer Ingelheim, which will combine Boehringer Ingelheim’s translational medicine and biomarker expertise with Berg’s next generation AI-driven, patient-biology capability,” he said. “Our intent is for BergInterrogative Biology platform to enable the discovery of biomarkers that will revolutionize how to diagnose and treat patients with inflammatory diseases.

Berg in the past has collaborated with numerous pharmaceutical companies and applied its Interrogative Biology platform to diverse datasets, in order to address major unment clinical needs.

Related news

Show more

Related products

show more

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us

Products

View more

Webinars